STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.

Also called NCT01927068

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 499 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01927068
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Austria, Belgium, France, Germany, Italy, New Zealand, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01927068. Non-randomized; no masking; primary purpose treatment. Start 2013-07 (actual); primary completion 2020-08 (actual). Results posted on 2022-03-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Acronym
ILLUMENATE
Condition
Peripheral Arterial Disease
Intervention (Device)
Stellarex 0.035" Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
Lead sponsor
Spectranetics Corporation (class: industry)

Record details

Record id
cardio:ct-nct01927068
Content hash
faf8d13941f83e2b09b945b893bdb38e41098bf5c2474960e2a477f08a9c8a0a